Introduction {#ss1}
============

MicroRNAs (miRNAs) are small non-coding RNAs belonging to a novel class of negative regulators that control gene expression by imperfect base pairing to the 3\` untranslated region (3\`UTR) of a target mRNA, leading to a protein translation inhibition or mRNA degradation ([@CIT0001]). MiRNAs are initially transcribed by RNA polymerase II as long primary precursors which are rapidly processed by an endonucleolytic multistep process into 18--22nt long mature miRNAs ([@CIT0002]). Once produced, miRNAs are loaded into the RNA-induced silencing complex (RISC) and guide the degradation or translational repression of the target mRNA([@CIT0003]). MiRNAs are found in the majority of multicellular and complex eukaryotes; it is currently estimated that miRNAs represent 1% of the predicted genes and that up to 10%--30% of human transcriptome is a direct target of miRNAs, indicating a pivotal role for miRNAs in almost every biological process, including cell cycle regulation, cell growth, apoptosis, cell differentiation, and stress response ([@CIT0001]). However, genetic analysis of *Caenorhabditis elegans* highlighted that only 10% of individual miRNA knock-outs have a distinct morphological and developmental defect ([@CIT0004]), illustrating the existence of functional redundancy among miRNAs or miRNA-regulated pathways. This redundancy shows that miRNAs may have evolved to control and refine specific aspects of terminal differentiation programs. Indeed, another important aspect of microRNA activity is represented by their ability to target thousands of genes per single miRNA, based on the 5\` end-restricted complementarity between animal miRNAs and mRNA targets (only five to eight nucleotides of perfect complementarity, termed 'seed sequence'). This target multiplicity may explain their ability to control several mRNAs that function in the same or similar processes. For example, miR-221 and miR-222 have been shown to activate cell proliferation by repressing a series of tumor suppressors, all of which are involved in cell cycle inhibition, like p27 ([@CIT0005]), its activator FOXO3a ([@CIT0006]), p57 ([@CIT0007]), BMF ([@CIT0008]), PTEN ([@CIT0009]), and APAF1 ([@CIT0010]).

Given their essential role in all the aspects of the cellular life, it is not surprising that miRNAs were found to cover important roles in tumorigenesis, and, since this discovery, over 5000 publications link miRNAs to cancer, including more than 1000 reviews. In this review we will outline the biological and molecular roles of miRNAs in cancer and metastasis by highlighting the most promising advances for the use of miRNAs in the clinical setting, both as direct and adjuvant chemotherapeutic agents.

MiRNAs in cancer {#ss2}
================

Genome-wide miRNA expression profiling analyses have reported a general dysregulation of miRNA expression in all tumors ([@CIT0011]). To date, over 1000 miRNAs have been reported in humans (miRbase: 1527 at November 2011), and hundreds of them map to chromosomic regions that are known to be altered in human cancer, such as loss of heterozygosity regions (LOH) (e.g. miR-15a/16-1), amplified regions (e.g. miR-17--92 cluster, miR-155), and breakpoint regions and fragile sites (FRA) (e.g. let-7 family members) ([@CIT0012]). Published studies have defined that elevated expression of some miRNAs (oncogenes) as well as down-regulation of others (tumor-suppressors) accompanies carcinogenesis and correlates with the development of cancer-associated phenotypes.

The first evidence of miR involvement in cancer came from our laboratory in 2004. We identified that the miR-15 and miR-16 genomic locus is heterozygously deleted in 68% of all patients with B-cell chronic lymphocytic leukemia (CLL) ([@CIT0013]). Loss of miR-15 and miR-16 reflects their tumor-suppressor function via uncontrolled expression of their anti-apoptotic target protein BCL2 in an *in vitro* model as well as in patient specimens of B-CLL ([@CIT0014]). Furthermore, a sequencing-based screen for miRNAs dysregulated in familial CLL patients identified a germ-line mutation in the primary precursor of miR-15a/16-1 that impairs their processing, highlighting that not only deletions but also mutations may lead to miRNAloss of function ([@CIT0015]). The importance of genetic lesions reducing miR-15/16-1 cluster expression in CLL was furthermore confirmed by the identification of a point mutation located in the 3\` flanking region of miR-16 that reduces miR-16 expression in a naturally occurring CLL mouse model, the New Zealand black (NZB) mouse, that develops a hematological disorder similar to the human CLL ([@CIT0016]). Even more definitive genetic evidence of the tumor-suppressive effects of miR-15 and miR-16 came recently from the Dalla-Favera lab where miR-15/16 knock-out mice were generated ([@CIT0017]). Targeted deletion of miR-15 and miR-16 in mice at the age of 18 months recapitulates the spectrum of CLL-associated lymphoproliferations in humans, including CLL, CD5(+) monoclonal B-cell lymphocytosis, and CD5- non-Hodgkin lymphomas ([@CIT0017]). Specifically, miR-15a/16-1 deletion accelerates the proliferation of both human and mouse B-cells by modulating the expression of genes controlling cell cycle progression like cyclin D3, cyclin E, CDK6, CHK1, and MCM5. However, the same authors also demonstrated that the size of 13q14 deletions, where the miR-15/16-1 cluster is located, influences the phenotype of lymphoproliferative disorders and potentially the severity of disease, suggesting a tumor suppressor function for genetic elements besides miR-15a/16-1 and their host gene DLEU2 ([@CIT0018]). In fact, an additional deletion of a 0.69 mb-large region telomeric to miR-15/16-1 increased the appearance of CLL, and mice seemed to succumb to their disease faster than miR-15/16-1-deleted mice. Deletion of the miR-15/16-1 cluster also occurs in other forms of tumors, such as multiple myeloma ([@CIT0019]) and prostate cancer ([@CIT0020]), indicating that the loss of these miRNAs could be relevant to other pathogenic events. In fact, the De Maria group demonstrated that, in prostate cancer, miR-15a/miR-16 levels are strongly down-regulated in the vast majority of cases (up to 85% of the analyzed samples) ([@CIT0020]). Interestingly, intraprostatic injection of miRNA antisense RNA oligonucleotide ('antagomirs') specific to miR-15a and miR-16 in 6-week-old male BALB/c mice resulted in marked hyperplasia, and knock-down of miR-15a and miR-16 promoted survival, proliferation, and invasiveness of untransformed prostate cells, which became tumorigenic in immunodeficient NOD-SCID mice ([@CIT0020]). Furthermore, they also demonstrated that miR-15 and miR-16 are down-regulated in fibroblasts surrounding the prostate tumors. Increased miR-15 and miR-16 expression in cancer-associated fibroblasts impaired tumor growth and expansion of prostate tumors in xenograft models through the reduced post-transcriptional repression of Fgf-2 and its receptor Fgfr1 ([@CIT0021]).

Similar to the down-regulation of the miR-15/16-1 cluster, another miRNA frequently lost in cancer is represented by the miR-34 family. These miRNAs, miR-34a on chromosome 1p36 and the miR-34b/c cluster on chromosome 11q23, are frequently deleted in neuroblastoma, breast, pancreas, hepatic, and colon carcinoma ([@CIT0022]). Loss of expression of the miR-34b/c cluster has also been associated with the hypermethylation of their CpG-associated promoter region in gastric cancer, while the same chromosomal region was not methylated in normal gastric mucosa ([@CIT0023]). The miR-34 family has been shown to be transcriptionally activated by p53, and it represents one of the main effectors of p53-induced apoptosis, senescence, and cell cycle arrest. These effects are achieved by repressing the expression of multiple oncogenes such as Notch-1 ([@CIT0024]), Notch-2 ([@CIT0024]), HMGA2 ([@CIT0024]), Myc ([@CIT0025]), several cyclins and CDKs ([@CIT0026]), CD44 ([@CIT0027]), the anti-apoptotic factor BCL2 ([@CIT0028]), and the p53 deacetylase SIRT1 ([@CIT0029]). Recently, miR-34 family knock-out mice have been generated, and no obvious developmental or pathological abnormalities were observed at up to 12 months of age ([@CIT0030]). However, the authors showed that miR-34-deficient mouse embryonic fibroblasts accelerate the reprogramming, not as expected through cell proliferation, but instead, at least partly, by post-transcriptional derepression of pluripotency genes, such as Sox2, N-Myc, and Nanog ([@CIT0030]). Many other miRNAs have been reported to act as tumor suppressors ([Table I](#T1){ref-type="table"}) by inhibiting tumor growth when expressed ectopically *in vitro* or *in vivo*; however, their bona fide tumor suppressor role is still missing. Examples include miR-26 ([@CIT0031; @CIT0032]), miR-143/145 cluster ([@CIT0033]), miR-181 family ([@CIT0034]), miR-200 family ([@CIT0035]), miR-203 ([@CIT0010; @CIT0036]), miR-31 ([@CIT0037]), and miR-192/194/215 ([@CIT0038]).

###### 

Tumor-suppressor miRs.

  miR                            Targets                                Tumor                                                                                                                                                          Impact on metastasis                                                                                                                  Description
  ------------------------------ -------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------
  miR-15/16                      BCL2                                   CLL                                                                                                                                                                                                                                                                                                  BCL2 repression by these microRNAs induces apoptosis in a leukemic cell line model
  COX-2                          Colon cancer                           miR-16 as a central post-transcriptional regulator of COX-2 and shows the ability of elevated levels of HuR to antagonize miR-16 function                                                                                                                                                            
  CHEK1                          Follicular lymphoma                    Distinct microRNA profiles are associated with an increased proliferative capacity and a 'late' germinal center B-cell phenotype                                                                                                                                                                     
  CEBPβ, CDC25a, CCNE1           Fibroblast                             Upon cell cycle re-entry, the rapid decay of miR-16 alleviates repression of target genes, allowing proper resumption of the cell cycle                                                                                                                                                              
  VEGF, VEGFR2, FGFR1            Fibroblast                             miR-16 plays important roles in regulating cell-intrinsic angiogenic activity of endothelial cells                                                                                                                                                                                                   
  FGF2, FGFR1                    Cancer-associated fibroblast           Down-regulation of miR-15 and miR-16 in cancer-associated fibroblasts (CAFs) promotes tumor growth and progression                                                                                                                                                                                   
  CCNE1                                                                 miR-15 and miR-16 families as novel transcriptional targets of E2F, which, in turn, modulates E2F activity                                                                                                                                                                                           
  FGFR1, PI3KCa, MDM4, VEGFa     Multiple myeloma                       Deletion of miR-15/16 is commonly observed in early stages of multiple myeloma                                                                                                                                                                                                                       
  WIP1                                                                  Role of miR-16 in the regulation of Wip1 phosphatase in the DNA damage response and mammary tumorigenesis                                                                                                                                                                                            
  BMI-1                          Ovarian cancer                         Bmi-1 is down-regulated by miR-15a or miR-16 expression and leads to reduction in ovarian cancer cell proliferation and clonal growth                                                                                                                                                                
  CCND1, CCND2, CCNE1            Lung cancer                            Overexpression of miR-15/16 induces arrest in G(1)-G(0)                                                                                                                                                                                                                                              
  miR-31                         ITGA5, RDX, RhoA, FZD3, M-RIP, MMP16   Breast cancer                                                                                                                                                  Suppresses                                                                                                                            miR-31 uses multiple mechanisms to oppose metastasis
  SATB2                          Cancer-associated fibroblast           New insights into tumor--stroma interaction and involvement of miR-31 in regulation of tumor cell motility                                                                                                                                                                                           
  miR-34                         SIRT1                                  Colon cancer                                                                                                                                                                                                                                                                                         miR-34 suppression of SIRT1 leads to apoptosis only in colon cancer cells with wild-type p53
  BCL2, NOTCH, HMGA2                                                    miR-34-mediated suppression of self-renewal is related to the direct modulation of the downstream targets Bcl-2, Notch, and HMGA2                                                                                                                                                                    
  MYC                            Fibroblast                             During senescence, miR-34a targets the proto-oncogene MYC and co-ordinately controls a set of cell cycle regulators                                                                                                                                                                                  
  AXL                            Lung cancer                            Axl receptor is regulated by miR-34a and miR-199a/b, suppressed by promoter methylation in solid cancer                                                                                                                                                                                              
  MET                            Ovarian cancer                         MET is a critical effector of p53, and inhibition of MET may be an effective antimetastatic approach to treat cancers with p53 mutations                                                                                                                                                             
  NANOG, SOX2, MYCN              Embryonic fibroblast                   Suppression of reprogramming by miR-34a due to repression of pluripotency genes                                                                                                                                                                                                                      
  SNAIL                          Colon cancer                           A new link between p53, miR-34, and Snail1 in the regulation of cancer cell EMT programs                                                                                                                                                                                                             
  miR-143/145                    KRAS, RREB1                            Pancreatic cancer                                                                                                                                                                                                                                                                                    miR-143/miR-145 are suppressed by KRAS through RREB1, revealing a feed-forward mechanism that potentiates Ras signaling
  KRAS, MYC, CCND2, CDK6, E2F3   Colon cancer                           EGFR suppresses miR-143 and miR-145 in murine models of colon cancer                                                                                                                                                                                                                                 
  BCL2                           Cervical cancer                        Promotion of apoptosis by miR-143 through the suppression of BCL2                                                                                                                                                                                                                                    
  PAI1                           Bladder cancer                         miR-145 and PAI1 as clinically relevant biomarkers in bladder cancer                                                                                                                                                                                                                                 
  PRC1, PLK1                     Liposarcoma                            The down-regulation of PRC1 and its docking partner PLK1 suggests that miR-143 inhibits cytokinesis in these cells                                                                                                                                                                                   
  MLL-AF4                        ALL                                    Therapeutic promise of up-regulating miR-143 expression for MLL-AF4 B-cell ALL                                                                                                                                                                                                                       
  MMP-13                         Osteosarcoma                           Down-regulation of miR-143 correlates with the lung metastasis of human osteosarcoma cells by promoting cellular invasion, probably via MMP-13 up-regulation                                                                                                                                         
  ERK5                           Burkitt lymphoma                       miRs-143 and -145 may be useful as biomarkers that differentiate B-cell malignant cells from normal cells                                                                                                                                                                                            
  Let-7 family                   KRAS                                   Lung cancer                                                                                                                                                                                                                                                                                          The let-7 family negatively regulates let-60/RAS in *C. elegans* and lung tumors
  HMGA2                                                                 Chromosomal translocations associated with human tumors disrupt repression of high mobility group A2 (Hmga2) by let-7 miRNA                                                                                                                                                                          
  MYC                            Burkitt lymphoma                       Dysregulation of let-7 participates in genesis and maintenance of Burkitt lymphoma and other MYC-dysregulated cancers                                                                                                                                                                                
  IMP-1                                                                 Let-7-oncofetal proteins could be novel therapeutic targets and potential biomarkers for cancer treatment                                                                                                                                                                                            
  DICER                                                                 Existence of a regulatory loop to regulate the equilibrated state of Dicer and various miRNAs                                                                                                                                                                                                        
  CDC-34                         Fibroblast                             Let-7 represses Cdc34, stabilizes Wee1 kinase, and increases a fraction of cells in G(2)/M in primary fibroblasts                                                                                                                                                                                    
  IL6                            Breast cancer                          Inflammation activates a positive feedback loop that maintains the epigenetic transformed state                                                                                                                                                                                                      
  E2F2, CCND2                    Prostate cancer                        Let-7a acts as a tumor suppressor in prostate cancer by down-regulating E2F2 and CCND2                                                                                                                                                                                                               
  BCL-XL                         Liver cancer                           Let-7 suppresses Bcl-xL expression in hepatocellular carcinomas and potentiates sorafenib-induced apoptosis                                                                                                                                                                                          
                                 PLCγ1                                  Breast cancer                                                                                                                                                  Tumor-suppressor function by negatively regulating EGF-driven cell invasion, viability, and cell cycle progression in breast cancer   
  miR-200 family                 ZEB1, ZEB2                             Breast cancer                                                                                                                                                  Suppresses                                                                                                                            Down-regulation of the miR-200 family may be an important step in tumor progression
  ERRFI-1                        Bladder cancer                         miR-200 is sufficient to restore EGFR dependency at least in some of the mesenchymal bladder cancer cells                                                                                                                                                                                            
  ZEB1, CTNNB1                   Nasopharyngeal carcinoma               The inhibitory effects of miR-200a on cell growth, migration, and invasion are mediated by distinct targets and pathways                                                                                                                                                                             
  BMI-1                          Pancreatic cancer                      ZEB1 links EMT and stemness maintenance by suppressing the miR-200 family and thereby promotes migration                                                                                                                                                                                             
  PLCγ1                          Breast cancer                          Tumor-suppressor function by negatively regulating EGF-driven cell invasion, viability, and cell cycle progression in breast cancer                                                                                                                                                                  
  FAP1                                                                  miR-200c sensitizes cells to apoptosis mediated by CD95                                                                                                                                                                                                                                              
  SUZ12                          Breast cancer                          The miR-200b-Suz12-cadherin pathway is important for cancer stem cell growth and invasive ability                                                                                                                                                                                                    
  FLT1/VEGFR1                    Lung cancer                            miR-200 suppresses lung adenocarcinoma metastasis by targeting Flt1 in tumor cells                                                                                                                                                                                                                   
  JAG1, MALM2, MALM3                                                    These findings explain increased Notch signaling in some types of cancers, where mutations in Notch pathway genes are rare                                                                                                                                                                           
  FN1, LEPR, NTRK2, ARHGAP19     Breast and endometrial cancer          miR-200c actively represses a program of mesenchymal and neuronal genes involved in cell motility and anoikis resistance                                                                                                                                                                             
  p38α                           Ovarian cancer                         miR-200a-dependent stress signature correlates with improved survival of patients in response to treatment                                                                                                                                                                                           

Although there seems to be a general trend towards down-regulation of microRNAs in cancer ([@CIT0039]), many different miRNAs follow the opposite pattern and, based on their ability to initiate or accelerate cancer, are named 'oncomiRs'. The first evidence of an oncogenic miRNAappeared in 2005 when the Mendell lab demonstrated that Myc can directly induce the expression of the polycistronic cluster miR-17/92 ([@CIT0040]). By using a reconstituted mouse model of Myc-induced lymphoma expressing a truncated version of the miR-17/92 cluster in hematopoietic cells, the authors showed an accelerated tumor development probably due to an anti-apoptotic mechanism associated with the suppression of their direct targets, such as inhibitors of proliferation CDKN1A ([@CIT0041]), direct regulators of the apoptosis PTEN ([@CIT0042]), and BCL2L11 (also known as BIM) ([@CIT0043]). This cluster has been shown to be up-regulated in many solid tumors such as breast, stomach, prostate, lung, and pancreas tumors ([@CIT0044]), and genetic deletion of the miR-17/92 cluster in mice highlighted their importance in B-cell development, as homozygous deletion of the cluster results in premature death of B-cells at the pro-B and pre-B stages, resulting in lymphopenia ([@CIT0045]). Interestingly, functional dissection of the miR-17/92 cluster in the context of B-cell transformation *in vivo* revealed that miR-19a and b mediate the oncogenic activity of the entire cluster, at least in part, by targeting the tumor suppressor PTEN and thereby activating Akt-mTOR signaling to promote cell survival ([@CIT0042]).

Another microRNAwith oncogenic activity is represented by miR-21, which is highly expressed in the majority of human malignancies thus far analyzed, including breast cancer ([@CIT0046; @CIT0047]), glioblastoma ([@CIT0048; @CIT0049]), hepatocellular carcinoma ([@CIT0050]), cholangiocarcinoma ([@CIT0051]), lung cancer ([@CIT0052]), tongue squamous cell carcinoma ([@CIT0053]), esophageal cancer ([@CIT0054]), stomach cancer ([@CIT0055]), colorectal cancer ([@CIT0056]), chronic myelogenous leukemia ([@CIT0057]), cervical cancer ([@CIT0058]), and prostate cancer ([@CIT0059]).

Experimental data indicate that miR-21 also plays a crucial role in tumor cell proliferation, apoptosis, and invasion, consistent with miR-21\'s ability to repress important tumor suppressors such as PTEN ([@CIT0050]), PDCD4 ([@CIT0056]), TPM-1 ([@CIT0060]), Tap-63 ([@CIT0061]), SPRY2 ([@CIT0062]), and hMSH2 ([@CIT0063]).

Recently, the Slack lab generated the first conditional knock-in of miR-21 overexpressing mice that showed a 15--30-fold induction of miR-21 ([@CIT0064]). These mice developed a severe pre-B-cell lymphoma, but when miR-21 was reduced to endogenous levels the mouse tumors completely disappeared, defining the concept of 'oncomiR addition' ([@CIT0064]). Interestingly, a 4--6-fold overexpression of miR-21 resulted in no obvious phenotype; however, miR-21 overexpression potentiates the lung tumorigenesis of a constitutively activated KRAS proto-oncogene ([@CIT0065]). Another *in vivo* evidence that miR-21 exerts an oncogenic function came from the DMBA-TPA skin carcinogenesis model used by Ma et al. on miR-21-null mice ([@CIT0066]). The miR-21 mice showed a significant reduction in papilloma formation compared with wild-type mice, with miR-21-null mice exhibiting an increase in cellular apoptosis and decrease in cell proliferation that is explained by the up-regulation of the miR-21 targets Spry1 ([@CIT0062]), Pten ([@CIT0050]), and Pdcd4 ([@CIT0056]).

Many other miRNAs have been reported to act as oncogenes ([Table II](#T2){ref-type="table"}) by inducing tumor growth, aggressiveness, and resistance to chemotherapy when expressed ectopically *in vitro* or *in vivo*: miR-155, miR-221, and miR-222 cluster, miR-9 and miR-103/107 family.

###### 

OncomiRs in action.

  miR                                               Targets                                                   Tumor                                                                                                                                                                                                               Impact on metastasis   Description
  ------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  miR-106a ∼ 363, miR-106b ∼ 25                     BIM, p21                                                  Gastric cancer                                                                                                                                                                                                                             The miR-106b-25 cluster is involved in E2F1 post-transcriptional regulation and may play a key role in the development of TGFβ resistance in gastric cancer
  E2F1                                              Prostate cancer                                           microRNA expression becomes altered with the development and progression of prostate cancer. Some of these microRNAs regulate the expression of cancer-related genes in prostate cancer cells                                              
  PTEN                                              Prostate cancer                                           Proto-oncogenic miRNA-dependent network for PTEN regulation                                                                                                                                                                                
  miR-21                                            PTEN                                                      Cholangiocarcinoma                                                                                                                                                                                                  Promotes               miR-21 modulates gemcitabine-induced apoptosis by phosphatase and the tensin homolog deleted on chromosome 10 (PTEN)-dependent activation of PI3-kinase signaling
  TPM1                                              Breast cancer                                             Suppression of miR-21 can inhibit tumor growth                                                                                                                                                                                             
  PDCD4                                             Breast cancer                                             The tumor suppressor protein programmed cell death 4 (PDCD4) is regulated by miR-21, and it has been demonstrated that PDCD4 is a functionally important target for miR-21 in breast cancer cells                                          
  SPRY1                                                                                                       miR-21-null mice show a significant reduction in papilloma formation compared with wild-type mice due to the up-regulation of its tumor-suppressor targets                                                                                 
  RECK, TIMP3                                       Glioblastoma                                              The inhibition of miR-21 provides a novel therapeutic approach for 'physiological' modulation of multiple proteins whose expression is deregulated in cancer                                                                               
  p63, JMY, TOPORS, TP53BP2, DAXX, HNRPK, TGFβRII   Glioblastoma                                              miR-21 targets multiple important components of p53, transforming growth factor-β (TGFβ), and mitochondrial apoptosis tumor-suppressive pathways                                                                                           
  MARKS                                             Prostate cancer                                           miR-21 could promote apoptosis resistance, motility, and invasion in prostate cancer cells                                                                                                                                                 
  ANP32A, SACA4                                     Prostate cancer                                                                                                                                                                                                                                                                                      
  miR-10a/10b                                       HOXB1, HOXB3                                              Pancreatic cancer                                                                                                                                                                                                   Promotes               miR-10a is a key mediator of metastatic behavior in pancreatic cancer that regulates metastasis via suppression of HOXB1 and HOXB3
  HOXD10                                            Breast cancer                                             TWIST transcription factor induces expression of a specific microRNA that suppresses its direct target and in turn activates another pro-metastatic gene, leading to tumor cell invasion and metastasis                                    
  KLF4                                              Esophageal cancer                                         A significant correlation of miR-10b level with cell motility and invasiveness                                                                                                                                                             
  TIAM1                                             Breast cancer                                             A mechanism for the regulation of Tiam1-mediated Rac activation in breast cancer cells                                                                                                                                                     
  Nf1                                               Ewing\'s sarcoma                                          miR-10b may play an important role in NF1 tumorigenesis through targeting neurofibromin and RAS signaling                                                                                                                                  
  miR-107/103                                       DICER                                                     Breast cancer                                                                                                                                                                                                       Promotes               Dicer inhibition drifts epithelial cancer toward a less-differentiated, mesenchymal fate to foster metastasis
  miR-9                                             PRDM1/Blimp-1                                             Lymphomas                                                                                                                                                                                                           Promotes               miRNA-mediated down-regulation of PRDM1/Blimp-1 may contribute to the phenotype maintenance and pathogenesis of lymphoma cells by interfering with normal B-cell terminal differentiation
  CDH1                                              Breast cancer                                                                                                                                                                                                                                                                                        
  CAMTA                                             Glioblastoma                                              miR-9 is highly expressed in glioblastoma cancer stem cells and reduces the levels of CAMTA tumor-suppressor                                                                                                                               
  miR-17--92                                        TSP-1, CTGF                                               Colon                                                                                                                                                                                                               Promotes               Up-regulated in colonocytes coexpressing K-Ras, c-Myc and p53 impaired activity
  E2F2, E2F3                                        Prostate/Burkitt lymphoma/testis carcinoma/               Presence of an autoregulatory feedback loop between E2F factors and miR-17/92                                                                                                                                                              
  BIM, PTEN                                         c-Myc-induced lymphoma                                    Transgenic mice with higher expression of miR-17/92 in lymphocytes                                                                                                                                                                         
  HIF1α                                             Lung cancer                                               Intricate and finely tuned circuit involving c-myc, miR-17/92, and HIF1α                                                                                                                                                                   
  PTPRO                                             Cervix tumor cell line                                    PTPRO gene is co-regulated by both E2F1 and miR-17/92 at transcriptional and post-transcriptional level, respectively                                                                                                                      
  p63                                               Myeloid cells                                             miR-92 increases cell proliferation by negative regulation of an isoform of the cell cycle regulator p63                                                                                                                                   
  BIM, PTEN, PRKAA1, PPP2R5e                        T-cell acute lymphoblastic leukemia                       Functional genomics approach reveals a co-ordinate clamp-down on several regulators of phosphatidylinositol-3-OH kinase-related survival signals by the leukemogenic miR-19                                                                
  JAK1                                              Endothelial cells                                         The miR-17/92 family may provide an interesting therapeutic perspective specifically to enhance therapeutic angiogenesis                                                                                                                   
  HBP1                                              Breast cancer                                             The miR-17/92 cluster plays an important role in breast cancer cell invasion and migration by suppressing HBP1 and subsequently activating Wnt/β-catenin                                                                                   
  p21(WAF1)                                         Ras-induced senescent fibroblasts                         Disruption of senescence by miR-17/92 or its miR-17/20a components leads to enhanced oncogenic transformation by activated Ras in primary human cells                                                                                      
  TGFβII SA4                                        Glioblastoma                                              miR-17/92 attenuates the TGFβ signaling pathway to shut down clusterin expression, thereby stimulating angiogenesis and tumor cell growth                                                                                                  
  MnSOD, GPX2, TRXR2                                Prostate                                                  miR-17/92 may suppress tumorigenicity of prostate cancer through inhibition of mitochondrial antioxidant enzymes                                                                                                                           
  miR-221/222                                       p27^kip1^                                                 Glioblastoma, prostate and thyroid carcinoma                                                                                                                                                                        Promotes               Certain cancer cell lines require high activity of miR-221/222 to maintain low p27^kip1^ levels and continuous proliferation
  p57^kip2^                                         Normal fibroblast                                         Up-regulation of miR-221/222 is tightly linked to the initiation of S phase with growth factor signaling pathways that stimulate cell proliferation                                                                                        
  PTEN, TIMP3                                       Non-small cell lung cancer and hepatocellular carcinoma   miR-221/222, by targeting PTEN and TIMP3 tumor suppressors, induce TRAIL resistance and enhance cellular migration. The MET oncogene is involved in miR-221/222 activation through the c-Jun transcription factor                          
  FOXO3A                                            Breast cancer                                             The miR-221/222 cluster targets FOXO3A to suppress p27^kip1^ also at a transcriptional level                                                                                                                                               
  KIT                                               Endothelial cells                                         Interaction between miR-222 and c-Kit is likely to be part of a complex circuit that controls the ability of endothelial cells to form new capillaries                                                                                     
  ESR1                                              Breast cancer                                             Modulation of ERα is associated with antiestrogen therapy                                                                                                                                                                                  
  PUMA                                              Glioblastoma                                              miR-221/222 directly regulate apoptosis by targeting PUMA in glioblastoma                                                                                                                                                                  
  TRSP1                                             Breast cancer                                             miR-221/222 promote EMT and contribute to the more aggressive clinical behavior of basal-like breast cancers                                                                                                                               
  PTPμ                                              Glioblastoma                                              miR-221/222 regulate glioma tumorigenesis at least in part through the control of PTPμ protein expression                                                                                                                                  
  DICER                                             Breast cancer                                             Dicer is low in ERα-negative breast cancers, since such cells express high miR-221/222                                                                                                                                                     
  APAF1                                             Non-small cell lung cancer                                miR-221/222 are modulated by both epidermal growth factor (EGF) and MET receptors, and, by targeting APAF1, miR-221/222 are responsible for gefitinib resistance                                                                           
  miR-155                                           SOCS1                                                     Breast cancer                                                                                                                                                                                                                              miR-155 is an oncomiR in breast cancer, and it has been suggested that miR-155 may serve as a bridge between inflammation and cancer
  CEBPB, PU.1, CUTL1, PICALM                        AML                                                       miR-155 as a contributor to physiological GM expansion during inflammation and to certain pathological features associated with AML                                                                                                        
  BACH1, ZIC3                                                                                                 The induction of miR-155 by EBV contributes to EBV-mediated signaling in part through the modulation of transcriptional regulatory factors                                                                                                 
  ETS1, MEIS1                                       Human cord blood CD34+                                    miR-155 is required for megakaryocytic proliferation and differentiation                                                                                                                                                                   
  C-MAF                                             Lymphocytes                                               bic/microRNA-155 plays a key role in the homeostasis and function of the immune system                                                                                                                                                     
  HGAL                                              Diffuse large B-cell lymphoma                             Cell dissemination and aggressiveness is a phenotype of DLBCL typically expressing high levels of miR-155 and lacking HGAL expression                                                                                                      
  JMJD1A                                            Nasopharyngeal carcinoma                                  Up-regulation of miR-155 is partly driven by LMP1 and LMP2A, and results in down-regulation of JMJD1A, associated with N stage and poor prognosis                                                                                          
  WEE1                                              Breast cancer                                             miR-155 enhances mutation rates by decreasing the efficiency of DNA safeguard mechanisms by targeting of cell cycle regulators such as WEE1                                                                                                
  TP53INP1                                          Pancreatic cancer                                         TP53INP1 expression is repressed by the oncogenic micro RNA miR-155, which is overexpressed in pancreatic carcinoma cells                                                                                                                  
  SMAD1, SA5, HIVEP2, CEBPB, RUNX2, MYO10                                                                     Role for miR-155 in controlling BMP-mediated cellular processes                                                                                                                                                                            
  FOXO3a                                            Breast cancer                                             Molecular links between miR-155 and FOXO3a affect cell survival and response to chemotherapy in breast cancer                                                                                                                              
  hMSH2, hMSH6, and hMLH1                           Colon cancer                                              Inactivation of mismatch repair is induced by miR-155                                                                                                                                                                                      
  SMAD5                                             Diffuse large B-cell lymphoma                             Highlighted a hitherto unappreciated role of SA5 in lymphoma biology and defined a unique mechanism used by cancer cells to escape TGFβ\'s growth-inhibitory effects                                                                       

MiRNAs in metastasis {#ss3}
====================

Accumulating data have pointed to a central regulatory role of miRNAs in the acquisition of invasive abilities and generation of the malignant phenotype that consists of loss of cellular adhesion, acquisition of cell motility, intra- and extravasation, and finally proliferation at a distant site. The first example of a 'metastamiR' is represented by miR-10a ([@CIT0067]). Weinberg\'s group demonstrated that miR-10a is overexpressed in about 50% of metastatic breast cancers and is transcriptionally activated by the pro-metastatic transcription factor TWIST1. Specifically, they demonstrated that miR-10a did not affect cell proliferation but instead promoted *in vitro* and *in vivo* migration, invasion, and metastasis of otherwise non-invasive breast cancer cells by repressing the homeobox protein D10, a transcription factor already known for its roles in cell motility. Contrary to miR-10a, miR-31 is highly down-regulated in metastatic breast cancer, and its overexpression strongly reduces metastatic spreading without affecting primary tumor growth ([@CIT0037]). MiR-31\'s actions on already-seeded lung metastases can be mediated via co-ordinate repression of a cohort of metastasis-promoting genes, including ITGA5, RDX, and RhoA.

The invasion--metastasis cascade, the multistep process whereby tumor cells disseminate from their primary site and survive in an ectopic microenvironment, can be explained molecularly by epithelial-to-mesenchymal transition (EMT). During EMT, an epithelial neoplastic cell loses cell adhesion by repressing E-cadherin expression, and thereby the cell increases its motility. Numerous studies have shown that different miRNAs are modulated during EMT, and one of the best-studied examples is represented by the miR-200 family. These miRs are commonly lost in aggressive tumors such as lung, prostate, and pancreatic cancer. It has been shown that miR-200 family members directly target ZEB1 and ZEB2, transcription repressors of E-cadherin ([@CIT0068]). In fact, in the highly aggressive mouse lung cancer model where KRAS is constitutively activated and p53 function is perturbed, miR-200 ectopic expression prevented metastasis by repressing ZEB1 and ZEB2 and preventing E-cadherin down-regulation ([@CIT0069]). However, overexpression of the miR-200 family is associated with an increased risk of metastasis in breast cancer, and this overexpression promotes metastatic colonization in mouse models, phenotypes that cannot be explained by E-cadherin expression alone ([@CIT0070]). By using proteomic profiling of the targets of MET-inducing miR-200, the authors discovered that miR-200 globally targets secreted proteins in breast cancer cells. Between the 38 modulated target genes, Sec23a, which is involved in transporting protein cargo from the endoplasmic reticulum to the Golgi, shows a superior association with human metastatic breast cancer as compared to the currently recognized miR-200 targets ZEB1 and the EMT marker E-cadherin. EMT is first acquired in the onset of transmigration and then reversed (mesenchymal-epithelial transition (MET)) in the new metastatic site. Korpal et al. have shown that the miR-200 status predicts predisposition of the cancer to successful metastasis ([@CIT0070]).

Another important study in the comprehension of miRNA involvement in metastatic spread came from the Massague lab, which has discovered that miR-335, miR-126, and miR-206 are lost in human lung and bone metastatic cells ([@CIT0071]). Overexpression of all three miRs suppressed the metastasis to lungs and bone in mice. Although miR-126 inhibits tumor growth and cell proliferation, miR-335 specifically suppresses metastatic invasion by repressing the transcription factor SOX4 and the extracellular matrix protein tenascin C. A further involvement of miR-126 in the metastatic setting was recently defined by the Tavazoie group ([@CIT0072]). They revealed that endogenous miR-126 non-cell-autonomously regulates endothelial cell recruitment to metastatic breast cancer cells, *in vitro* and *in vivo*. Specifically, it suppresses metastatic endothelial recruitment, metastatic angiogenesis, and metastatic colonization through co-ordinate targeting of IGFBP2, PITPNC1, and MERTK---novel pro-angiogenic genes and biomarkers of human metastasis.

New therapeutic approaches using miRNAs {#ss4}
=======================================

The strong involvement of miRNAs in cancer appearance, development, and progression provides a rationale for the therapeutic approach to miRNAs in cancer treatment. During the years of miRNA research, several strategies have been pursued, and they can be recapitulated essentially in miRNA-based therapy and miRNA-adjuvant therapy. The first approach will consist in reducing/increasing miRNA levels (oncomiRs/tumor suppressor) and/or interfering with the miRNA/mRNA interaction. As a therapeutic possibility, miRNAs may be used as single molecules or in a combinatorial way to target one or multiple genes. For example, if a mutation is altering the binding site for a miRNA, combining two or three miRNAs can overcome the therapy unresponsiveness. In addition, a combination of antagomiRs for oncomiRs and miRNA mimics for tumor-suppressors may represent a future approach. The first example to be cited in this area is the therapeutic use of let-7 molecules in lung cancer. Let-7 has been shown to be down-regulated in a large fraction of human cancers, and low levels of hsa-let-7a expression are correlated with poor survival of lung cancer patients ([@CIT0044; @CIT0073]). Intratumoral injection of liposome-pre-let-7 molecules in preformed lung tumor xenografts resulted in the strong inhibition of overall tumor growth ([@CIT0074]). However, this delivery route might be inadequate in a clinical setting, as peripheral tumor cells remained present and showed limited knock-down of let-7 targets by immunohistochemistry. Another approach with potential for translation into clinical settings is the use of a neutral lipid emulsion (NLE). NLE has shown tumor-inhibitory effects of let-7 NLE formulations in a mouse model of lung cancer (a transgenic mouse with a constitutively activated KRAS) with an already established lung tumor ([@CIT0075]). Another interesting approach of miRNA-based therapies came from Dr Mendell\'s lab. MiR-26a is strongly down-regulated in hepatocellular carcinoma (HCC) as compared with paired non-cancerous tissues, and miR-26a\'s low expression is associated with a shorter overall survival but a better response to interferon therapy ([@CIT0076]). Mendell\'s lab demonstrated that systemic delivery of a miR-26a-expressing adenoviral particle via tail intravenous injections into a MYC-induced hepatocellular carcinoma mouse model resulted in inhibition of cancer cell proliferation, induction of tumor-specific apoptosis, and dramatic protection from disease progression, without toxicity ([@CIT0077]). However, the therapeutic approach of miR-26a needs to be carefully considered based on the fact that miR-26a has been found to be up-regulated in T-ALL patients and its expression enhanced leukemogenesis in a mouse model of T-ALL by suppressing the levels of PTEN and BIM tumor suppressor protein ([@CIT0077]).

A recent work by Hatziapostolou and co-workers defined a new player in hepatocarcinogenesis and new potential targets for the treatment of HCC ([@CIT0078]). The authors identified the existence of a positive feedback loop involving miR-24/miR-629/HNF4alpha/miR-124/STAT3/IL-6R, in which perturbations amplify and perpetuate the knock-down of HNF4alpha, thereby inducing liver cancer. To test the relevance of this novel inflammatory circuitry *in vivo*, they delivered miR-124 to the liver during diethylnitrosamine (DEN)-induced hepatocarcinogenesis by using tail injection of a miR-124 precursor liposome particle. Not only did miR-124 reduce the number of carcinogen-induced tumors by 90% when administered throughout the entire study, but it also led to a striking 80% decrease when treatment was started only 4 weeks before sacrifice. Even considering that therapeutic success in mouse models is not always reproducible in humans, this study demonstrated the efficacy of miR-124 in the treatment of liver cancer, and more importantly it opens the possibility of using miR-124 therapy in the advanced stages of HCC.

As previously stated, only the 'seed sequence' of a miRNA is required to identify the appropriate mRNA target, and miRNA'target multiplicity' is the natural consequence of the small number of bases required for miRNA function. Therefore, blocking the function of a single miRNA that is dysregulated in a neoplastic state can have a major effect on disease progression, because it will reactivate the expression of a large fraction of genes. However, this reactivation is not a simple task, as different miRNAs can target the same sequence and miRNAs have identical seeds but differ in the non-seed region. In fact, the traditional 15-mer antagomiR would target more than the seed sequence, thereby generating the potential for large, off-target inhibition of other miRNAs. The solution appears to be selectively inhibiting miRNAs using only the seed as a target. Sakari Kauppinen and colleagues described an important new strategy for silencing the function of miRNAs after investigating the functional consequences of targeting only the seed sequence ([@CIT0079]). They found that targeting the seed region with a perfectly matched 8-base antimiR potently inhibited miR-21 function and resulted in up-regulation of a miR-21 target protein ([@CIT0079]). Moreover, by targeting the seed region of let-7, they showed how it is possible to block the function of an entire family of microRNAs. A key feature of this approach for future therapy is the simple systemic delivery; in fact, intravenously injected tiny LNAs (locked nucleic acid: chemically modified ribonucleotides) are taken up by a range of mouse tissues, such as breast, lung, and liver, which leads to long-lasting silencing of miRNA function.

The second clinical application of miRNAs is related to a more therapeutic value of miRNAs as acute, rather than chronic, adjuvant targets. This application is essentially supported by the numerous studies describing the modulation of cell sensitivity to chemotherapeutic agents after miRNA expression modulation. A majority of these studies note the identification of modulated miRNAs in cells resistant to chemotherapeutic drugs. In this regard, the first story that we would like to illustrate came from our laboratory and describes the involvement of the miR-221 and miR-222 cluster in TNF-related apoptosis-inducing ligand (TRAIL)- and gefitinib-resistance of non-small cell lung cancer (NSCLC) ([@CIT0010; @CIT0080; @CIT0009]). In 2005, our lab addressed the implication of miRNAs in TRAIL-resistance of non-small cell lung carcinoma, and we found that miR-221 and miR-222 were markedly up-regulated in TRAIL-resistant and semi-resistant cells compared to TRAIL-sensitive NSCLC cells. Specifically, we demonstrated that silencing p27^kip1^ but not Kit, both functional targets of miR-221 and miR-222, increased resistance to TRAIL ([@CIT0080]). This result supports well the involvement of miR-221 and miR-222 in determining the TRAIL-resistant/sensitive phenotype in NSCLC cells mainly by miR-221 and miR-222 interfering with p27^kip1^ expression and TRAIL-induced caspase machinery. Recently, we also reported that the hepatocyte growth factor receptor (MET) oncogene, through c-Jun transcriptional activation, up-regulates miR-221 and miR-222 expression, which, in turn, by targeting PTEN and TIMP3, confers resistance to TRAIL-induced cell death and enhances tumorigenicity of lung and liver cancer cells ([@CIT0082]). The results suggest that therapeutic intervention involving the use of miRNAs should not only sensitize tumor cells to drug-inducing apoptosis, but also inhibit their survival, proliferation, and invasion. In our most recent manuscript, we explored the involvement of MET-modulated miR-221 and miR-222 in the development of *de novo* and acquired resistance of lung cancer cells to tyrosine kinase inhibitors, such as gefitinib, the first line of treatment for EGFR-positive lung cancer patients ([@CIT0010]). We demonstrated that these two miRNAs are regulated by both MET and EGFR receptors in lung cancer cells, and more importantly, that their expression levels are down-regulated upon gefitinib treatment only in gefitinib-sensitive cells but not in resistant cells because of MET overexpression. We also demonstrated that gefitinib resistance could be overcome by MET inhibitors, which down-regulate miR-221 and miR-222 and sensitize lung cancer cells to gefitinib, or by anti-miR-221 and anti-miR-222, which strongly increase gefitinib sensitivity *in vitro* and in xenograft mouse models *in vivo* ([@CIT0010]). Another interesting application of miR-221 and miR-222 on drug resistance has been described in tamoxifen resistance in breast cancer. Tamoxifen is one of the most widely used selective estrogen receptor modulators in breast cancer therapy for estrogen receptor-positive patients. One of the main problems related to its use is the appearance of tamoxifen resistance in a large fraction of patients who initially respond to the therapy. Majumder\'s group demonstrated in 2008 that miR-221 and miR-222 are the most modulated miRNAs in cells with acquired resistance to tamoxifen ([@CIT0081]). Interestingly, ectopic expression of miR-221 and miR-222 rendered the parental cells resistant to tamoxifen, and the effect was partially related to the down-regulation of the cell cycle inhibitor p27^kip1^, a known target of miR-221 and miR-222. Up-regulation of miR-221 and miR-222 has also been implicated in resistance to drugs such as fulvestrant ([@CIT0082]) and cisplatin ([@CIT0083]) in breast cancer, castration-resistant prostate cancer ([@CIT0084]), TRAIL-resistant non-small cell lung cancer cells ([@CIT0080]), and radiation-resistant gastric carcinoma cells ([@CIT0085]).

Another interesting story that relates microRNA expression to chemoresistance is represented by the ability of miR-21 to modulate the sensitivity of cancer cells to 5-fluoruracil (5-FU). High levels of miR-21 were correlated with a very low response to therapy and poor outcome in colorectal cancer patients ([@CIT0086]); the low response to the drug is partially associated to reduced levels of core mismatch repair mutator genes ([@CIT0063]). Interestingly, inhibition of miR-21 expression was able to sensitize cells to 5-FU, suggesting that miR-21 inhibition may represent a future way to overcome cell resistance to traditional chemotherapy ([@CIT0063]). Like miR-21, miR-34 has also been shown to modulate cancer cell sensitivity to 5-FU ([@CIT0087]). In this case, ectopic expression of miR-34 in colorectal cancer cells inhibited cell proliferation and sensitized cancer cells to 5-FU. However, miR-34 inhibition has been shown to enhance the apoptotic response to bortezomib in Myc-transformed B-cells, clearly demonstrating that miRNA involvement in chemotherapy is context-dependent ([@CIT0088]).

Conclusion {#ss5}
==========

MiRNAs continue to reveal high diversity and complexity in their biological functions and involvement in disease. However, despite remarkable recent progress, the connection between cancer and miRNAs remains incompletely understood, and many open questions remain with regard to the possible application of miRNAs in therapy. First, based on the miRNA target multiplicity and tissue-dependent effects, one of the main goals of future miRNA research must be the identification of the widespread effects on the transcriptome of every single miRNA. To this aim, genome-wide analyses will need to delineate the global alterations in miRNA genes or copy number alterations in various human tumors in order to identify all of the putative tumor-suppressor and oncogenic miRNAs. At the same time, more sophisticated *in vivo* models are needed to identify and define miRNA functions. Because miRNAs can have widespread effects on the transcriptome, their full biological properties are unlikely to be explained by the suppression of a single or few proteins. In fact, the major challenge is to define all of the mRNA targets and cancer-related pathways that are controlled by the dysregulated miRNAs in neoplasia. Unmistakably, miRNAs have a role in cancer, and the major challenge is to recognize the impact on the networks rather than on a few isolated targets. With this aim, new sophisticated computational target prediction methods will be helpful. Although miRNAs only moderately suppress their targets, miRNAs could exert both strong and broad effects, largely because they suppress many genes and because they are implicated in multiple feedback loops with other regulators of gene expression. Exploring the roles of miRNAs in these intimate cross-talks will help us to understand the causes of cancer and other diseases and in creating new alternative therapeutics.
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